ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
A Transformative Wearable Corneal Microneedle Patch for Efficient Therapy of Ocular Injury and Infection.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Dissolving microneedle patches loaded with resveratrol albumin nanoclusters for corneal anti-angiogenic therapy.International journal of pharmaceutics: X · 2026Article
- Smart contact lenses unlocking non-invasive eye treatment.Fundamental research · 2026Review
- Microneedle technology in the treatment of ocular diseases: Advances and applications.Asian journal of pharmaceutical sciences · 2026Review
- Bacteria microenvironment-responsive missile microneedles modulate immunity and penetrate biofilm for diabetic wound therapy.Bioactive materials · 2026Article
- Current progress in research on ocular injury caused by exposure to vesicants.Progress in retinal and eye research · 2025Review
- Development and Evaluation of Cyclosporine a Mixed Micelle Eye Drops for Enhanced Ocular Drug Delivery.AAPS PharmSciTech · 2025Article
- A Transformative Wearable Corneal Microneedle Patch for Efficient Therapy of Ocular Injury and Infection.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Recent Achievements and Perspectives in Smart Nano-in-Micro Platforms for Ocular Disease Treatment.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Ocular injury and infection are significant causes of vision impairment and blindness globally. Effective treatment is, however, challenging due to the physical barrier of the cornea, which restricts drug penetration in the eye, as well as the presence of eye injury that necessitates continuous delivery of growth factors on the ocular surface for cornea healing. Here, we introduce a transformative wearable corneal microneedle (MN) patch designed for efficient therapy of ocular injury and infection. The MN patch comprises water-soluble tips that encapsulate antibacterial nanoparticles (NPs), along with a transformative backing layer that contains epidermal growth factor (EGF). Upon insertion into the eye, the MN tips dissolve swiftly within the cornea stroma, resulting in the release of the antimicrobial NPs to efficiently eradicate bacteria. Meanwhile, the residual backing layer undergoes rapid in situ transformation upon contact with mildly acidic fluid from infected corneal edema, converting into a contact lens that conforms to the eye's surface, which facilitates sustained release of EGF on the ocular surface over 8 h to promote corneal healing. Benefiting from these features, the designed transformative corneal MN patch demonstrates superior efficacy in treating ocular injuries and infections in vivo, offering a promising therapeutic strategy to manage eye diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.